Miv-cel CD19 CAR T-Cell Therapy in Stiff Person Syndrome (SPS) in a Pivotal, Multicenter, Phase 2 Study (KYSA-8): Efficacy and Biomarker Analysis of Patients With ≥6 Months of[...]

Kyverna Therapeutics Inc. published this content on November 06, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 13, 2026 at 13:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]